Funke, Manuela; Geiser, Thomas (2015). Idiopathic pulmonary fibrosis: the turning point is now! Swiss medical weekly, 145, w14139. EMH Schweizerischer Ärzteverlag 10.4414/smw.2015.14139
|
Text
smw-2015-14139.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial-No Derivative Works (CC-BY-NC-ND). Download (1MB) | Preview |
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with poor survival. Recent studies have improved understanding of IPF and new discoveries have led to novel treatment options, which now have become available for patients. In face of the newly available therapies we present an update on the pathophysiology and epidemiology of IPF. We discuss the typical clinical findings and elaborate diagnostic procedures according to current guidelines and our daily practice approach. The role of biomarkers will briefly be outlined. Finally, we discuss novel antifibrotic treatment options for IPF (pirfenidone, nintedanib) and the management of patients regarding to comorbidities and complications. Both pirfenidone and nintedanib were shown to reduce the progression of IPF and therefore represent novel therapeutic strategies in this so far untreatable chronic lung disease.
Item Type: |
Journal Article (Review Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Gastro-intestinal, Liver and Lung Disorders (DMLL) > Clinic of Pneumology |
UniBE Contributor: |
Funke, Manuela, Geiser, Thomas (A) |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
1424-7860 |
Publisher: |
EMH Schweizerischer Ärzteverlag |
Language: |
English |
Submitter: |
Rahel Holderegger |
Date Deposited: |
06 Apr 2016 08:53 |
Last Modified: |
29 Mar 2023 23:34 |
Publisher DOI: |
10.4414/smw.2015.14139 |
PubMed ID: |
26024356 |
BORIS DOI: |
10.7892/boris.78846 |
URI: |
https://boris.unibe.ch/id/eprint/78846 |
Actions (login required)
 |
Edit item |